Resources from the same session
1O - Chemotherapy and liver transplantation versus chemotherapy alone in patients with definitively unresectable colorectal liver metastases: Updated results from the randomized TRANSMET trial
Presenter: Maximiliano Gelli
Session: Proffered Paper session
Resources:
Abstract
Slides
Webcast
2O - Health-related quality of life (HRQoL) with first-line (1L) nivolumab (NIVO) plus ipilimumab (IPI) vs chemotherapy (chemo) in patients (pts) with microsatellite instability-high (MSI-H)/mismatch repair-deficient (dMMR) metastatic colorectal cancer (mCRC):
Presenter: Sara Lonardi
Session: Proffered Paper session
Resources:
Abstract
Slides
Webcast
3O - PRODIGE 68 - UCGI 38 - SOREGATT: A randomized phase II study comparing the sequences of regorafenib (reg) and trifluridine/tipiracil (t/t) after failure of standard therapies in patients (pts) with metastatic colorectal cancer (mCRC)
Presenter: Michel Ducreux
Session: Proffered Paper session
Resources:
Abstract
Slides
Webcast
Q&A and discussion
Session: Proffered Paper session
Resources:
Webcast
LBA3 - Final analysis of the phase III KEYNOTE-585 study of pembrolizumab plus chemotherapy vs chemotherapy as perioperative therapy in locally-advanced gastric and gastroesophageal junction cancer
Presenter: Kohei Shitara
Session: Proffered Paper session
Resources:
Abstract
Slides
Webcast
LBA4 - Switch maintenance with ramucirumab plus paclitaxel versus continuation of oxaliplatin-based chemotherapy in advanced HER2-negative gastric or gastroesophageal junction (GEJ) cancer: Final results and key biomarkers of the ARMANI phase III trial
Presenter: Giovanni Randon
Session: Proffered Paper session
Resources:
Abstract
Invited discussant LBA3 and LBA4
Presenter: Elizabeth Smyth
Session: Proffered Paper session
Resources:
Slides
Webcast
Q&A and discussion
Session: Proffered Paper session
Resources:
Webcast